Company Overview and News
The local stock barometer slightly rebounded yesterday, tracking an intraday recovery across regional markets after the initial jitters caused by the sharp decline in the value of the Chinese yuan.
ABZPF SMIVY PSKXF SVTMF ABZPY AYAAY PHSXY SM PSE ALI AYAAF AP
THE Philippine Stock Exchange index (PSEi) finished at a one-month high on Wednesday, drawing strength from Wall Street’s rise on Federal Reserve Chairman Jerome Powell’s optimistic remarks on the US economy and solid earnings results.
SMIVY SSI SHAK SVTMF MWP AYAAY SM MWIDE ALI AYAAF
Shares advanced on Wednesday, July 18, boosted by the positive performance of international markets after United States Federal Reserve Chairman Jerome Powell hinted at more flexible changes in monetary policy.
SVTMF PSKXF AYAAY SM SMIVY SSI SHAK MWP PHSXY PSE MWIDE ALI AYAAF
The bellwether Philippine Stock Exchange index (PSEI) snapped its four-day winning streak Monday, July 16, dropping 29.74 points or 0.4% to end at 7,369.44, while the broader all-shares index gave up 12.29 points or 0.27% to finish at 4,462.60.
SVTMF PSKXF BDOUY AYAAY SM BDOUF BDO SMIVY MWP PHSXY PSE MWIDE ALI AYAAF
(July 13): Southeast Asian stock markets edged higher on Friday, with Indonesia and Malaysia extending gains to a fifth consecutive session, as worries over U.S.-China trade tensions eased.
SMPH SMIVY SVTMF SPHXY SM SPHXF SPHZF
(July 11): Southeast Asian stock markets fell on Wednesday, with Singapore erasing some of the last two sessions' gains and Vietnam extending losses to a third session, as Washington warned of tariffs on an additional US$200 billion worth of Chinese imports, escalating the trade dispute.
SMIVY SVTMF SM PETFF
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET